Toggle light / dark theme

The Tesla Model Y has topped Sweden’s automotive registrations regardless of powertrain type in the first half of 2024, as shown in new data.

The Model Y was the most-registered vehicle in Sweden in the first six months of this year, according to data from Mobility Sweden reported by Carup on Monday. The Model Y topped the charts overall with 7,386 units registered, despite a 20 percent decline in overall EV sales. The Model 3 landed 14th overall in the six-month period, while electric options from Volvo, Toyota, Polestar, and Volkswagen were also some of the most registered.

“It is gratifying that the proportion of electric cars reached the best for the year in June, but at the same time we see a stagnant market, which leads to a gradually aging vehicle fleet,” said Mattias Bergman, CEO of Mobility Sweden. “In order to meet the climate goals and strengthen Sweden’s competitiveness, it is crucial that electrification is accelerated.”

MD Anderson researchers identify molecule that reduces age-related inflammation and improves brain and muscle function in preclinical models.

MD Anderson News Release June 21, 2024

Researchers at The University of Texas MD Anderson Cancer Center have demonstrated that therapeutically restoring…


The study, published today in Cell, identified a small molecule compound that restores physiological levels of telomerase reverse transcriptase (TERT), which normally is repressed with the onset of aging. Maintenance of TERT levels in aged lab models reduced cellular senescence and tissue inflammation, spurred new neuron formation with improved memory, and enhanced neuromuscular function, which increased strength and coordination.

Most of our progress in disease treatment and prevention to date has been the product of the linear process of hit-or-miss efforts to find useful interventions. Because we have lacked tools for systematically exploring all possible treatments, discoveries under this paradigm have owed a lot to chance. Likely the most notable chance breakthrough in medicine was the accidental discovery of penicillin — which opened up the antibiotic revolution and has since saved perhaps as many as 200 million lives. But even when discoveries aren’t literally accidental, it still takes good fortune for researchers to achieve breakthroughs with traditional methods. Without the ability to exhaustively simulate possible drug molecules, researchers have to rely on high-throughput screening and other painstaking laboratory methods, which are much slower and more inefficient.

To be fair, this approach has brought great benefits. A thousand years ago, European life expectancy at birth was just in the twenties, since so many people died in infancy or youth from diseases like cholera and dysentery, which are now easily preventable. By the middle of the nineteenth century, life expectancy in the United Kingdom and the United States had increased to the forties. As of 2023, it has risen to over eighty in much of the developed world. So, we have nearly tripled life expectancy in the past thousand years and doubled it in the past two centuries. This was largely achieved by developing ways to avoid or kill external pathogens — bacteria and viruses that bring disease from outside our bodies.

Today, though, most of this low-hanging fruit has been picked. The remaining sources of disease and disability spring mostly from deep within our own bodies. As cells malfunction and tissues break down, we get conditions like cancer, atherosclerosis, diabetes, and Alzheimer’s. To an extent we can reduce these risks through lifestyle, diet, and supplementation — what I call the first bridge to radical life extension. But those can only delay the inevitable. This is why life expectancy gains in developed countries have slowed since roughly the middle of the twentieth century. For example, from 1,880 to 1900, life expectancy at birth in the United States increased from about thirty-nine to forty-nine, but from 1980 to 2000 — after the focus of medicine had shifted from infectious disease to chronic and degenerative disease — it only increased from seventy-four to seventy-six.

Positive life experiences boost brain mitochondrial health, potentially providing protection against certain brain disorders and promoting longevity.

In @MedicalXpress: https://ow.ly/BNn750SrT3c.

In PNAS: https://ow.ly/wT1e50SrT3b.

Mitochondria supply energy to the brain, and the new study shows that…


Psychosocial experiences affect brain health and aging trajectories, but the molecular pathways underlying these associations remain unclear. Normal brain function relies on energy transformation by mitochondria oxidative phosphorylation (OxPhos). Two main lines of evidence position mitochondria both as targets and drivers of psychosocial experiences. On the one hand, chronic stress exposure and mood states may alter multiple aspects of mitochondrial biology; on the other hand, functional variations in mitochondrial OxPhos capacity may alter social behavior, stress reactivity, and mood. But are psychosocial exposures and subjective experiences linked to mitochondrial biology in the human brain?

Cirrus Therapeutics, the University of Bristol, and London’s Global University Institute of Ophthalmology have discovered a new treatment for age-related macular degeneration (AMD), the leading cause of vision loss among older adults.

Featured on the cover of the journal Science Translational Medicine, this research reveals that boosting a specific protein, IRAK-M, in retinal cells could offer a new and highly effective therapy for AMD.

AMD can severely impact a person’s vision. Patients suffering from AMD often start with blurred vision or seeing a black dot in their central vision, which can ultimately expand to the point where there is no useful central vision. Currently, AMD affects approximately 200 million people worldwide, a number projected to rise to 288 million by 2040 with graying populations. The exact cause of AMD is complex and thought to involve a combination of aging, environmental, and lifestyle factors.